US 12,234,505 B2
Spatially encoded biological assays
Mark S. Chee, San Diego, CA (US)
Assigned to Prognosys Biosciences, Inc., San Diego, CA (US)
Filed by Prognosys Biosciences, Inc., San Diego, CA (US)
Filed on Aug. 2, 2024, as Appl. No. 18/793,359.
Application 18/793,359 is a continuation of application No. 18/100,127, filed on Jan. 23, 2023.
Application 18/100,127 is a continuation of application No. 17/878,519, filed on Aug. 1, 2022, granted, now 11,560,587, issued on Jan. 24, 2023.
Application 17/878,519 is a continuation of application No. 17/556,588, filed on Dec. 20, 2021, granted, now 11,401,545, issued on Aug. 8, 2022.
Application 17/556,588 is a continuation of application No. 17/223,669, filed on Apr. 6, 2021, granted, now 11,208,684, issued on Dec. 28, 2021.
Application 17/223,669 is a continuation of application No. 17/030,230, filed on Sep. 23, 2020, granted, now 11,384,386, issued on Jul. 12, 2022.
Application 17/030,230 is a continuation of application No. 16/988,284, filed on Aug. 7, 2020, granted, now 10,961,566, issued on Mar. 30, 2021.
Application 16/988,284 is a continuation of application No. 16/414,213, filed on May 16, 2019, granted, now 10,787,701, issued on Sep. 29, 2020.
Application 16/414,213 is a continuation of application No. 16/402,098, filed on May 2, 2019, granted, now 10,472,669, issued on Nov. 12, 2019.
Application 16/402,098 is a continuation of application No. 16/276,235, filed on Feb. 14, 2019, granted, now 10,480,022, issued on Nov. 19, 2019.
Application 16/276,235 is a continuation of application No. 15/187,661, filed on Jun. 20, 2016, granted, now 10,308,982, issued on Jun. 4, 2019.
Application 15/187,661 is a continuation of application No. 13/080,616, filed on Apr. 5, 2011, granted, now 9,371,598, issued on Jun. 21, 2016.
Claims priority of provisional application 61/321,124, filed on Apr. 5, 2010.
Prior Publication US 2024/0392351 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6837 (2018.01); B01L 3/00 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6804 (2018.01); C12Q 1/6809 (2018.01); C12Q 1/6834 (2018.01); C12Q 1/6841 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6876 (2018.01); C40B 30/04 (2006.01); C40B 60/04 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01); G01N 33/68 (2006.01); C12Q 1/6858 (2018.01)
CPC C12Q 1/6837 (2013.01) [B01L 3/502715 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6804 (2013.01); C12Q 1/6809 (2013.01); C12Q 1/6834 (2013.01); C12Q 1/6841 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6874 (2013.01); C12Q 1/6876 (2013.01); C40B 30/04 (2013.01); C40B 60/04 (2013.01); G01N 33/5308 (2013.01); G01N 33/543 (2013.01); G01N 33/54366 (2013.01); G01N 33/6845 (2013.01); G01N 33/6848 (2013.01); C12Q 1/6858 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2458/10 (2013.01); G01N 2458/40 (2013.01)] 27 Claims
 
1. A method of determining spatial distribution of target biological molecules in a tissue sample, comprising:
(a) providing the tissue sample comprising the target biological molecules;
(b) allowing the target biological molecules to interact with nucleic acid probes;
(c) coupling encoded oligonucleotides to the nucleic acid probes, wherein the encoded oligonucleotides are arranged according to a known spatial pattern;
(d) determining sequences of the encoded oligonucleotides coupled to the nucleic acid probes; and
(e) mapping the target biological molecules to locations in the tissue sample using the sequences of the encoded oligonucleotides.